-
1 month ago | 
ionanalytics.com | Christel Thunell |William Cain |Lloyd Vassell
M&A deal volume in the obesity drug sector slimmed down in 2024 compared to 2023, while the industry holds its breath awaiting new technologies and regulatory clarity, sector experts said. The slowed dealmaking is just down to a temporary lack of appetite, rather than a long-term tightening of the belt – future M&A prospects in the sector remain exciting, they said.
-
Jan 21, 2025 | 
ionanalytics.com | Christel Thunell |Lucy Chapman
News (Intelligence) BioMerieux [EPA:BIM], a French in vitro diagnostics company, is keen to make more acquisitions and has financial headroom of EUR 3bn-EUR 4bn for M&A, CEO Pierre Boulud said. The EUR 12.9bn market-cap company has a low debt level and is cashflow generating, so it can finance acquisitions relatively easily, Boulud told this news service on the sidelines of the J.P. Morgan Healthcare Conference in San Francisco last week.
-
Nov 18, 2024 | 
ionanalytics.com | Taku Dzimwasha |Rachel Lewis |Christel Thunell |Raj Saiya
Stada Arzneimittel AG’s long-anticipated listing could be the tonic healthcare IPOs need to supercharge volumes again. As previously reported, the German pharma heavyweight, backed by Bain and Cinven, is pressing ahead with its IPO plans for next year, raising optimism for the healthcare sector. In 2024 YTD, healthcare IPOs have reached USD 3.7bn, this is up from USD 2.5bn in 2023. Volumes this year were boosted by the IPO of Galderma [SIX: GALD] in March; a USD 2.6bn deal.
-
Nov 14, 2024 | 
ionanalytics.com | Christel Thunell |Lloyd Vassell
SummaryFocus on oncology and neuroscience, also rare diseasesCan look further afield for licensing deals, including ChinaVenture capital-type investments also consideredIpsen [EPA:IPN], a French biopharmaceutical company, continuously looks for M&A deals, with EUR 2bn of financing capability in cash and debt facilities, Executive Vice President and Chief Business Officer Philippe Lopes-Fernandes said. The EUR 9bn market cap company is debt-free, the exec said.
-
Nov 11, 2024 | 
ionanalytics.com | Sam Kerr |Rachel Lewis |Christel Thunell |Lloyd Vassell
Investors focusing on large-cap listings likely to get index inclusionMid-cap IPO candidates must be cheap or uniqueSponsors focusing on middle market with large-cap financing difficultA new structural dynamic appeared in the European capital markets in 2024, one that is predicted to continue into 2025, of a disparity in strategic options available for sellers of large and mid-cap companies.
-
Sep 5, 2024 | 
ionanalytics.com | Christel Thunell |Lloyd Vassell
Healthy as well as sugary snacks, ice cream hit the sweet spotLikely has EUR 35bn-plus spending powerHas the muscle to do mammoth deal like Froneri, Unilever ice creamThe Ferrero Group, a family-owned, Italian sweet packaged-food company, will look at acquisitions in snacking, confectionery, chocolate, mints, biscuits and ice cream, with a focus on Europe and the US, three sources familiar with the company told Mergermarket.
-
Aug 28, 2024 | 
ionanalytics.com | Christel Thunell |Santosh Shetty |Lloyd Vassell
The bicycle industry has gone through a strange cycle in the last few years, which has in turn led to a bumpy M&A market. But the sector is pedalling towards the light at the end of the tunnel. “We are very confident that the M&A market will open again around 2Q25-3Q25”, said Thomas Egli, Managing Director at Houlihan Lokey. Dealmaking in the sector peaked in 2022, when 23 European deals were logged with aggregate volumes of EUR 1.8bn.
-
Aug 8, 2024 | 
ionanalytics.com | Gabriele Rutkauskaite |Christel Thunell |Saritha Dantu |Lloyd Vassell
Breweries could pursue further deals in bottling sector amid supply chain simplificationCategory lines between brewing and soft drinks starting to blur with zero and low-alcohol alternativesBritvic takeover boosts EMEA beverages M&A to EUR 5.6bn, already ahead of 2023 full-year tallyEurope’s beverages sector is poised for further M&A across bottling and soft drinks driven by the need for consolidation, diversification, and adaptation to consumer trends, according to sector dealmakers.
-
Jun 11, 2024 | 
ionanalytics.com | Myriam Mariotte |Gabriele Rutkauskaite |Christel Thunell |Amaya Urgoiti Basurto
French frozen bakery maker Mademoiselle Desserts and its majority owner, IK Partners, are working with financial advisor BNP Paribas on an upcoming sale of the company, three sources familiar with the matter and a sector player said. Although a formal mandate has not yet been signed, there is “no doubt” that BNP Paribas will lead the sale, one source added. Mademoiselle Desserts has already hired a separate, undisclosed, advisor to kick off vendor due diligence, according to the same source.
-
May 27, 2024 | 
ionanalytics.com | Nelson Rodrigues |Rachel Lewis |Christel Thunell |Iñaki Miguel
News (Intelligence) The sale of FairJourney Biologics has moved to the second round and the company has attracted the interest of private equity firms Advent International and KKR & Co [NYSE:KKR], sources familiar with the situation said. The Portuguese contract research organisation (CRO), backed by specialist healthcare sponsor GHO Capital, had mandated JP Morgan earlier this year, as reported.
